Dan Becker
Principal @ Access Biotechnology
San Mateo, United States
Dan Becker is a Series B investor at Access Biotechnology in San Mateo focused on Biotechnology and Pharmaceutical. Dan Becker joined New Leaf Venture Partners in 2015. Prior to joining New Leaf, Dan was a Principal at the Boston Consulting Group where he was a core member of their Health Care practice and led projects across the health care sector with an emphasis on biopharma R&D. Prior to BCG, Dan was a Research Fellow at Harvard Medical School, andtrained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital. Dan graduated summa cum laude with a B.S. in Physiology from the University of Illinois at Urbana-Champaign, and obtained both his M.D. and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan. Dan has co-authored multiple scientific publications in peer-reviewed journals, including Nature Genetics and the Journal of Cell Biology. He is Board-certified in Internal Medicine.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Dan Becker invests in
Stages Dan Becker invests in
Countries Dan Becker invests in
Investment Focus
Industry
- Biotechnology 9 (60%)
- Pharmaceutical 7 (47%)
- Health Care 5 (33%)
- Medical 3 (20%)
- Biopharma 3 (20%)
Stage
- Series B 6 (40%)
- Series A 5 (33%)
- Pre-Seed 1 (7%)
- Series C 1 (7%)
- Post-IPO Equity 1 (7%)
Country
- United States 9 (60%)
- Denmark 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Day One Biopharmaceuticals
|
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of peopleof all ages living with cancer starting from the biology of childhood cancer.Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA. | $175M / Post-IPO Equity / Jul 30, 2024 | |
GRO Biosciences
|
GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars. | $60.3M / Series B / Jul 19, 2024 | |
Mariana Oncology
|
Mariana Oncology is a biotechnology research industry. | $175M / Series B / Sep 07, 2023 | |
Hemab
|
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $135M / Series B / Feb 21, 2023 | |
Zurp
|
Zurp is a fintech platform built for superfans. Instead of a traditional reward program, Zurp offers exclusive experiences with cardholders' favorite influencers. | $5M / Pre-Seed / Jan 24, 2023 | |
Matchpoint Therapeutics
|
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology. | $70M / Series A / Oct 14, 2022 | |
ACELYRIN
|
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients. | $300M / Series C / Sep 13, 2022 | |
Curie Therapeutics
|
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emittingradionuclide payloads. | $75M / Series A / Dec 01, 2021 | |
|
Mariana Oncology
|
Mariana Oncology is a biotechnology research industry. | $75M / Series A / Dec 01, 2021 | |
DTx Pharma
|
DTx Pharma develops technology that will unleash RNA-based therapeutics as the modality of choice for personalized treatment across therapeutic areas. DTx Pharma believes its approach to delivering RNA medicines solves some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake. | $100M / Series B / Mar 01, 2021 | |
| See all 15 investments → | |||
Co-Investors
About Access Biotechnology
Access Biotechnology is the life science investment arm of Access Industries. They invest in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. They invest in both private and public biopharma companies across therapeutic areas, modalities, and development stages – fromdiscovery-stage technology platforms to late-stage clinical programs.The company is based in New York.
Access Biotechnology Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christine Borowski
Senior Associate
|
|||
|
Dan Becker
Principal
|
|||
Jeffrey Ives
Advisor
|
|||
Liam Ratcliffe
Head of Biotechnology
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dan Becker invest in?
Dan Becker invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dan Becker last invest?
The most recent investment recorded for Dan Becker closed in Jul 2024. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
